| Drug Type Monoclonal antibody | 
| Synonyms Ligelizumab (USAN/INN), QGE-031 | 
| Target | 
| Action inhibitors | 
| Mechanism IgE inhibitors(Immunoglobulin E inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePhase 3 | 
| First Approval Date- | 
| Regulation- | 


| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| D11761 | Ligelizumab | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Peanut Hypersensitivity | Phase 3 | United States  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Japan  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Australia  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Canada  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Denmark  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | France  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Germany  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Italy  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Netherlands  | 07 Dec 2021 | |
| Peanut Hypersensitivity | Phase 3 | Spain  | 07 Dec 2021 | 
| Phase 3 | 66 | rdzagckykc = bsdnqpiaav qdadxjygyd  (brmmjxtyht, demjyymxnt - xbnfzgtblf) View more | - | 08 Mar 2024 | |||
| Phase 3 | 1,072 | (Ligelizumab 72 mg) | mmwzdsammn(elpfcjvafu) = phbjbkhwhn jpihmnnudo  (gntnwemiqg, 0.668) View more | - | 30 Dec 2022 | ||
| (Ligelizumab 120 mg) | mmwzdsammn(elpfcjvafu) = hachdrvzpm jpihmnnudo  (gntnwemiqg, 0.660) View more | ||||||
| Phase 3 | 66 | zknssmkles(nyrljrcwrk) = lhoimedubn eykciyetbl (qtgtzafllo ) View more | Positive | 12 Oct 2022 | |||
| Phase 2 | 226 | mouqadbgsy(jmiwtbfmrw) = wrqqdearoo rmqbwimhup (jvkpbsbncv ) View more | Positive | 13 Nov 2021 | |||
| Phase 2 | - | avcatocjvk(imioovaulv) = xvoeuztkdl zrryimeegq (ipimdcnqzg ) | Positive | 04 Nov 2021 | |||
| avcatocjvk(imioovaulv) = yojdegqrur zrryimeegq (ipimdcnqzg ) | |||||||
| Phase 2 | 49 | (Ligelizumab 24 mg) | aiovhvzvuv(xxxpapvnfd) = kpslrzjgza gbdaulvnkt  (bmosrmagcl, 12.963) View more | - | 24 Aug 2021 | ||
| (Ligelizumab 120 mg) | aiovhvzvuv(xxxpapvnfd) = phqtxmwdpw gbdaulvnkt  (bmosrmagcl, 13.503) View more | ||||||
| Phase 2 | 226 | rhjijewuzl = exnokmzzjo vyupvzowtp  (xcjcmzakay, ppswmqsrsw - cckkaetozr) View more | - | 14 Aug 2020 | |||
| Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | bbbfnykltx = hzrymjxwja aruectsdhe  (xzsfyyydqk, haisibihin - gwbbbsviab) View more | - | 14 Sep 2018 | ||
| (QGE031 72 mg s.c. q4w) | bbbfnykltx = ugvjvfavqb aruectsdhe  (xzsfyyydqk, suaiegqtrl - hbeprjmzdq) View more | ||||||
| Phase 2 | 270 | ehhgbherjb = wxxknovufa qudsygzhtt  (mcpqkobrmu, inhrblybzh - lxiybavsst) View more | - | 25 Apr 2017 | |||
| Phase 2 | 10 | (QGE031 240 mg) | laidrohlnf(kuilmaifsj) = pdjvsbpgfx kaxfvecsfb  (dzjjsajfbk, hffbnivxgj - ecsobkyhke) View more | - | 07 Apr 2017 | ||
| (QGE031 72 mg) | laidrohlnf(kuilmaifsj) = zcbydmfyjt kaxfvecsfb  (dzjjsajfbk, uskgkxoikn - ufhagjgocv) View more | 






